Elite Pharmaceuticals launched a generic version of Requip XL, expanding its controlled-release portfolio with a newly commercialized product.
Targets a market with USD 10 million in US sales over the 12 months ended June 2026, supporting incremental revenue potential.
Launch strengthens Elite’s competitive position in niche generics through in-house manufacturing and nationwide distribution under its Elite Laboratories label.
ELTP•
